RIT Logo
RIT Home Search A-Z Index Directories myRIT
College of Science
COS Home
About the College
Academic Programs
Cooperative Education
Facilities
Advising/Student Services
Student Life
Research Partnerships
Alumni Services
News & Events
Departments & Contacts
Admission & Financial Aid
Distinguished Speaker Robert Rose, PhD
Thursday April 8, 2010 - 4-5pm
Chester F. Carlson Center for Imaging Science auditorium (76-1125)


Robert_Rose
RosePoster

Robert Rose, PhD
Departments of Medicine and Microbiology and Immunology
University of Rochester Medical Center

 
“Development of an effective, licensed vaccine for cervical cancer…
the rest of the story….“
 
ABSTRACT:To the general public, the sudden appearance in 2006 of a vaccine capable of preventing uterine cervical cancer came with little warning. In reality, concerted efforts by several groups, including our own, over a roughly 20 year period had preceded FDA approval. In this presentation I will provide a detailed description of efforts by each of the various groups involved as events unfolded. Thus far, those efforts have led to the approval of two vaccines (GardasilTM by Merck in 2006, and CervarixTM by GSK in 2009) designed to prevent the precursor lesions of cervical cancer and (with regard to Gardasil) benign anogenital warts. In addition to development and clinical testing, the pre-approval period was characterized by concerted efforts to obtain intellectual property rights for the production and use of these human papillomavirus (HPV) virus-like particle (VLP)-based vaccine formulations. Lastly, the often vigorous controversy that arose primarily as a result of governmental efforts to mandate universal vaccination of pre-adolescent females will be discussed, along with other potentially useful applications for these promising new vaccines.

Related links ;

A Cancer Vaccine Is Born

Robert Rose Associate Professor of Medicine, and of Microbiology and Immunology